Original ReportA Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain
Under an Elsevier user license
open archive
Key words
Alvimopan
peripherally acting mu-opioid receptor (PAM-OR) antagonist
pain
opioid analgesics
constipation
Cited by (0)
Supported by GlaxoSmithKline (GSK). Funding for medical editorial assistance for this manuscript was provided by Adolor Corporation, Exton, Pennsylvania, and GlaxoSmithKline, Philadelphia, Pennsylvania.
Copyright © 2011 American Pain Society. Published by Elsevier Inc. All rights reserved.